Syncom Formulations Upgraded to Hold as Technicals Improve Amid Mixed Financial Trends

Technical Trends Show Signs of Stabilisation

The primary catalyst for the upgrade was a notable change in the technical grade, which moved from bearish to mildly bearish. While the weekly and monthly MACD indicators remain bearish and mildly bearish respectively, other technical signals suggest a less pessimistic outlook. The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, indicating a neutral momentum.

Bollinger Bands on weekly and monthly timeframes remain mildly bearish, but the daily moving averages have also softened to mildly bearish, reflecting a potential bottoming process. The KST indicator, a momentum oscillator, remains bearish weekly but mildly bearish monthly, while Dow Theory readings have improved to mildly bullish on a weekly basis, though no trend is established monthly. On-Balance Volume (OBV) shows no clear trend, suggesting volume is not strongly favouring either buyers or sellers at present.

These technical nuances have contributed to a more balanced view of the stock’s near-term price action. The stock price itself has responded positively, closing at ₹14.38 on 9 Feb 2026, up 6.13% from the previous close of ₹13.55, with intraday highs touching ₹14.50. This price remains well below the 52-week high of ₹23.46 but comfortably above the 52-week low of ₹11.52, indicating some recovery potential.

Financial Performance Remains a Bright Spot

Syncom Formulations has demonstrated very positive financial results in the recent quarter (Q2 FY25-26), which have supported the upgrade decision. The company reported an 8.29% growth in operating profit, continuing a streak of six consecutive quarters of positive results. Net sales for the latest six months stood at ₹238.62 crores, growing 25.87% year-on-year, while profit after tax (PAT) surged by 72.46% to ₹32.32 crores over the same period.

Return on Capital Employed (ROCE) for the half-year reached a robust 22.06%, signalling efficient capital utilisation. Return on Equity (ROE) is also healthy at 16.6%, supporting the company’s ability to generate shareholder value. The company’s low average debt-to-equity ratio of 0.05 times further underlines its conservative financial structure, reducing risk from leverage.

Valuation Metrics Reflect Fair Pricing Amid Premium

Despite the positive financial momentum, valuation remains a mixed factor. Syncom Formulations trades at a Price to Book (P/B) ratio of 3.6, which is a premium compared to its peers’ historical averages. The Price/Earnings to Growth (PEG) ratio is notably low at 0.2, suggesting that the stock’s price growth is undervalued relative to its earnings growth potential.

However, the stock’s one-year return of -22.02% contrasts sharply with a 90.1% increase in profits over the same period, indicating a disconnect between market pricing and fundamental performance. This divergence may reflect market scepticism or concerns about the company’s longer-term growth prospects.

Quality Assessment Highlights Mixed Long-Term Growth

While recent quarters have been encouraging, the company’s long-term growth trajectory remains a concern. Over the past five years, net sales have declined at an annualised rate of -63.63%, and operating profit has contracted by -52.27%. This poor long-term growth weighs on the overall quality grade and tempers enthusiasm for a stronger upgrade.

Additionally, domestic mutual funds hold a negligible stake in Syncom Formulations, signalling limited institutional confidence. Given that mutual funds typically conduct thorough on-the-ground research, their absence may indicate reservations about the company’s price or business model.

Comparative Market Performance

Syncom Formulations has outperformed the Sensex over longer horizons but underperformed in the recent year. The stock’s three-year return of 96.99% and five-year return of 338.41% significantly exceed the Sensex’s 38.25% and 63.78% respectively, while the ten-year return of 379.33% also surpasses the Sensex’s 249.97%. However, in the last 12 months, the stock has generated a negative return of -22.02%, compared to the BSE500’s positive 9.00% return, highlighting recent challenges.

Summary and Outlook

The upgrade of Syncom Formulations from Sell to Hold reflects a balanced assessment of its current standing. Improved technical indicators, particularly the shift from bearish to mildly bearish trends, have reduced near-term downside risk. Meanwhile, strong recent financial results, including double-digit growth in sales and profits, support a more positive outlook.

However, the company’s valuation remains somewhat stretched relative to peers, and its long-term growth record is disappointing. The lack of institutional ownership further suggests caution. Investors should weigh these factors carefully, recognising that while the stock shows signs of recovery and operational strength, it still faces significant challenges in regaining sustained market confidence.

For now, the Hold rating and a Mojo Score of 51.0 reflect a neutral stance, signalling that Syncom Formulations may be suitable for investors seeking exposure to the Pharmaceuticals & Biotechnology sector with a moderate risk appetite and a focus on improving fundamentals.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →